VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
VACCINEX, INC.
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026
- Market cap
- $3.22M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.52 (+108.3%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
VACCINEX, INC. grew revenue 5.4% to $601.00K over the twelve months to Dec 31, 2024. Free cash flow was -$16.21M.
Revenue
$601.00K
+5.4% vs. a year earlier
Operating income
-$18.74M
TTM Q4 2024
Free cash flow
-$16.21M
TTM Q4 2024
EPS, diluted
-$8.88
TTM Q4 2024
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Dec 31, 2024
Valuation
- Market cap
- $3.22M
- P/E ratio
- –
- Price to sales
- 5.36
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -502.80%
Fundamentals
- Revenue
- $601.00K
- Net income
- -$18.63M
- EPS, diluted
- -$8.88
- Free cash flow
- -$16.21M
- Diluted shares
- 3M
Nine years at a glance
Fiscal years 2016 to 2024, USD
Revenue
$601.00K+5.4% YoY
Gross profit
–
Operating income
-$18.74M
Net income
-$18.63M
EPS, diluted
-$8.88
Free cash flow
-$16.21M
Reported period